Vamil Divan
Stock Analyst at Guggenheim
(4.56)
# 189
Out of 4,829 analysts
231
Total ratings
62.42%
Success rate
14.46%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $6.38 | +119.44% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $188.10 | +14.83% | 25 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $6 | $0.56 | +969.33% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $79.31 | +45.00% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $20.67 | +127.38% | 8 | Apr 14, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $63.66 | +35.09% | 10 | Apr 11, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $153.74 | - | 15 | Apr 2, 2025 | |
| ASMB Assembly Biosciences | Initiates: Buy | $31 | $12.36 | +150.81% | 1 | Mar 25, 2025 | |
| ABSI Absci | Reiterates: Buy | $10 | $2.84 | +252.11% | 3 | Mar 20, 2025 | |
| PFE Pfizer | Reiterates: Buy | n/a | $22.86 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $22.87 | +166.72% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $67.41 | +49.83% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.60 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.74 | +710.81% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $6.67 | +199.85% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.39 | +6,517.46% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.97 | +832.16% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.08 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $17.17 | +10.66% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $118.71 | -17.45% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $31.02 | +9.61% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.27 | +690.51% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $106.20 | -53.86% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $732.98 | -51.43% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.73 | +26.85% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $20.67 | +645.04% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $9.86 | +52.13% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.43 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $17.73 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.07 | +269.00% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $47.33 | +28.88% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $0.78 | +13,037.76% | 3 | Jan 17, 2018 |
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $6.38
Upside: +119.44%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $188.10
Upside: +14.83%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $6
Current: $0.56
Upside: +969.33%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $79.31
Upside: +45.00%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $20.67
Upside: +127.38%
ANI Pharmaceuticals
Apr 11, 2025
Reiterates: Buy
Price Target: $86
Current: $63.66
Upside: +35.09%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $153.74
Upside: -
Assembly Biosciences
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $12.36
Upside: +150.81%
Absci
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.84
Upside: +252.11%
Pfizer
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $22.86
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $22.87
Upside: +166.72%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $67.41
Upside: +49.83%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.60
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.74
Upside: +710.81%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $6.67
Upside: +199.85%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.39
Upside: +6,517.46%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.97
Upside: +832.16%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $17.17
Upside: +10.66%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $118.71
Upside: -17.45%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $31.02
Upside: +9.61%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.27
Upside: +690.51%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $106.20
Upside: -53.86%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $732.98
Upside: -51.43%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.73
Upside: +26.85%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $20.67
Upside: +645.04%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $9.86
Upside: +52.13%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $25.43
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $17.73
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.07
Upside: +269.00%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $47.33
Upside: +28.88%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $0.78
Upside: +13,037.76%